Untitled Document
Express Press Release Distribution
Home Page
Submit Press Release
EPR Nationwide Sites
Browse By Industries
Search Press Releases
About EPR
Help Pages
Contact Us
Disclaimer
Privacy Policy
Terms of Service
 
 
 
 
Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel
 

EPR Archived News

Archived News 2009
~ December
~ November
~ October
~ September
~ August
~ July

~ June
~ May
~ April
~ March
~ February

~ January

Archived News 2008
~ December
~ November
~ October
~ September
~ August
~ July

~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2007
~ December
~ November
~ October
~ September
~ August

~ July

~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2006
~ December
~ November
~ October
~ September
~ August
~ July

~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2005
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2004
~ December
~ November
~ October
~ September
~ August
~ July

 

 

 

 

New Medicine Ultram is now available for chronic pain

Released on = November 16, 2006, 12:29 am

Press Release Author = Olivia Andrews

Industry = Pharmaceuticals

Press Release Summary = Tramadol Ultram has played a major role in the treatment of
different sort of pains ranging from acute too chronic pain.

Press Release Body = A large number of people suffer from different sort of pains
either acute to moderate to severe pain and almost 50 million Americans suffer from
chronic pain. FDA has also approved Ultram in September 2005 based upon a safety and
clinical data after undergoing clinical trials.

Seizures have been reported in patients receiving tramadol. The risk of seizure is
increased with doses of tramadol above the recommended range and in patients taking
certain medications such as tricyclic antidepressants, selective serotonin reuptake
inhibitors, or opioids. Administration of tramadol may enhance the seizure risk in
patients taking MAO inhibitors, neuroleptics, other drugs that reduce the seizure
threshold, or in patients with epilepsy, those with a history of seizures, or in
patients with a recognized risk for seizure (such as head trauma, metabolic
disorders, alcohol and drug withdrawal, CNS infections).

\"Chronic pain affects a large segment of the U.S. population, with an estimated 45
percent of all Americans seeking care for persistent pain at least once during their
lifetime,\" according to Dr. Fernandes

The development of a once-daily formulation of tramadol is indicative of how an
innovative drug-delivery technology can overcome the most difficult formulation
enhancement challenges,\" said Douglas.

Tramadol, like other opioids used in analgesia, can be abused. ULTRAM should not be
used in patients who are suicidal or addiction-prone, or taken with
alcohol-containing beverages.

For more information, visit our website http://www.benzer11.com/ultram.html to know
about approved medicines and treatments.



Web Site = http://www.benzer11.com

Contact Details = Binghamton, NY 13902
email: webmaster@benzer11.com

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •  

     

     

    Untitled Document

     

    Submit Press Release (Free)Submit Press Release

     

    Press Release ForumPress Release Forum

     

    Press Release BlogPress Release Blog

     

     

     

     

     

    About | Submit Press Release | Help | Search | Links | Nationwide / EPR Network

    © 2004-2009 Express-Press-Release.Net. Part of EPR-Network.com. All Rights Reserved. All trade marks and names are owned by their respective owners
    Link to Us / Privacy / Disclaimer / Feedback -- Questions, Suggestions, Comments at E-mail: info@EPR-Network.com
    EPR disclaims any content found in press releases -- full disclaimer can be found here

    Contextually linked in LinkedWords

     

     
    Express Press Release Distribution